Protooncogene MDM2 SNP309 (rs2279744) Analysis of Polymorphism in Thyroid Cancer: Pakistani Population

MDM2 has been found to be a major adverse regulatory factor for p53 and to be associated with increased expression of MDM2 with the substantially earliest onset age of some tumors, including thyroid cancer, with single nucleotide polymorphism (SNP) in the SNP309 promoter region of MDM2. The purpose of this study was to evaluate the association between thyroid risk and polymorphism of MDM2 SNP309 in Pakistani people. We performed case-control work to test this relationship. The power of the association was measured by odds ratios and confidence intervals (CIs) of 95%. For the codominant model, dominant model and recessive model, the ORs were performed together, respectively. The case-control investigation was conducted with 120 cases of thyroid and 70 controls. The risk of MDM2 SNP309 multiplied with the thyroid risk (GG vs. TT; OR = 1.54; 95% CI = 1.04-2.29; and GG vs. GT/TT, OR = 1.42, 95% CI = 1.30-1.72) had been significantly increased. The findings indicate that polymorphism MDM2 SNP309 is a low penetration risk factors for the development of men's thyroid cancer.